<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJPN</journal-id><journal-title-group><journal-title>International Journal of Psychiatry and Neurology</journal-title></journal-title-group><issn pub-type="epub">2166-5788</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/IJPN.2017.62002</article-id><article-id pub-id-type="publisher-id">IJPN-20732</article-id><article-categories><subj-group subj-group-type="heading"><subject>IJPN20170200000_52884702.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  Tau的异常磷酸化与Tau病
  Abnormally Phosphorylated Tau and Tauopathies
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>亦刚</given-names></name><xref ref-type="aff" rid="aff1"><sub>1</sub></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>武汉科技大学医学院，湖北 武汉</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>1480716351@qq.com</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>05</month><year>2017</year></pub-date><volume>06</volume><issue>02</issue><fpage>7</fpage><lpage>12</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   Tau蛋白是脑内非常重要的微管相关蛋白。其异常磷酸化在神经退行性疾病中起重要的作用。Tau病是一种tau蛋白异常疾病的总称，即神经细胞内、神经胶质细胞内异常磷酸化tau蛋白蓄积的神经变性疾病。在tau蛋白某些区域的过度磷酸化可影响tau与微管的结合能力，更为严重的是，tau蛋白的过度磷酸化可促进和增强tau蛋白的聚集。许多证据表明，在阿尔茨海默病(AD)及其他tau蛋白引起的病理过程中tau蛋白的过度磷酸化可能发生在最早期。Tau蛋白发生过度磷酸化可能是蛋白激酶活性上调或磷酸酯酶活性下调造成。AD等神经退行性疾病的发生机制尚不明确。对tau蛋白的相关功能及调控机制进行深入的研究可能为了解神经退行性疾病的临床和病理生理机制提供某些新的思路，为此类疾病的早期诊断和治疗提供一定的依据。 Tau is the very important microtuble-associated protein in the brain. Abnormally phosphorylated tau plays an important effect. Tauopathy is a total name of the diseases aroused by abnormal tau protein, being the neurodenatured diseases with the accumulation of abnormally phosphorylated tau in the neural cells and neuroglias. The hyper-phosphorylation at some regions of tau may affect the binding ability of tau with the microtuble, and being severer, the hyper-phosphorylation can improve and enhance the accumulation of tau. There are many evidences, that manifested the hyper-phosphorylation of tau protein may happen in the most early stage in the pathological courses of Alzheimer’s disease and the other diseases caused by the abnormal tau protein. Hyper-phosphorylation of tau protein can be caused by the up-regulation of the activity in the protein kinases or the down-regulation of the activity in the protein phosphatases. It is still not clear how do happen the neurodegenerative diseases such as AD and so on. The deep researches about the relative function and regulation-control mechanism of tau protein maybe provide some new thinking for us understanding the clinic and pathophysiological mechanism, and offer certain bases for the diagnosis and treatment in the early stage of the diseases.
    
  
 
</p></abstract><kwd-group><kwd>蛋白质，Tau，异常磷酸化，Tau病，功能障碍, Protein</kwd><kwd> Tau</kwd><kwd> Abnormal Phosphorylation</kwd><kwd> Tauopathy</kwd><kwd> Dysfunction</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Tau的异常磷酸化与Tau病<sup> </sup></title><p>陈亦刚</p><p>武汉科技大学医学院，湖北 武汉</p><p>收稿日期：2017年5月6日；录用日期：2017年5月24日；发布日期：2017年5月27日</p><disp-formula id="hanspub.20732-formula1"><graphic xlink:href="http://html.hanspub.org/file/1-2240067x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>Tau蛋白是脑内非常重要的微管相关蛋白。其异常磷酸化在神经退行性疾病中起重要的作用。Tau病是一种tau蛋白异常疾病的总称，即神经细胞内、神经胶质细胞内异常磷酸化tau蛋白蓄积的神经变性疾病。在tau蛋白某些区域的过度磷酸化可影响tau与微管的结合能力，更为严重的是，tau蛋白的过度磷酸化可促进和增强tau蛋白的聚集。许多证据表明，在阿尔茨海默病(AD)及其他tau蛋白引起的病理过程中tau蛋白的过度磷酸化可能发生在最早期。Tau蛋白发生过度磷酸化可能是蛋白激酶活性上调或磷酸酯酶活性下调造成。AD等神经退行性疾病的发生机制尚不明确。对tau蛋白的相关功能及调控机制进行深入的研究可能为了解神经退行性疾病的临床和病理生理机制提供某些新的思路，为此类疾病的早期诊断和治疗提供一定的依据。</p><p>关键词 :蛋白质，Tau，异常磷酸化，Tau病，功能障碍</p><disp-formula id="hanspub.20732-formula2"><graphic xlink:href="http://html.hanspub.org/file/1-2240067x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by author and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>Tau是脑内含量最多的微管相关蛋白，其异常磷酸化与多种脑疾病相关。</p></sec><sec id="s4"><title>2. Tau的概述</title><p>Tau蛋白是一种微管相关蛋白，主要分布在神经元，其次是在神经胶质细胞。正常情况下，转录后的tau发生磷酸化修饰而有利于微管的稳定 [<xref ref-type="bibr" rid="hanspub.20732-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.20732-ref2">2</xref>] 。但过磷酸化则可导致神经组织内各种类型的细胞骨架变形、聚集，进而丧失正常的功能。</p><p>在人脑神经元中tau蛋白由16个外显子构成的单基因(至少100 kb)编码，位于17q21。在成年人大脑中根据tau蛋白基因的不同剪切，有6种亚型，分别以Tau1-6命名 [<xref ref-type="bibr" rid="hanspub.20732-ref3">3</xref>] 。根据Tau蛋白的羧基端有无外显子2和外显子3，分为如下三种形式：1) 外显子2和外显子3均无表达(A0)；2) 表达外显子2(A1)；3) 表达外显子2和外显子3(A2)。接续羧基端的是脯氨酸富含区域与微管结合区域，后者有两种形式：3R tau含有3个微管结合区域(不表达外显子10)或4R tau含有4个微管结合区域(表达外显子10)。Tau蛋白按分子量可分为：小分子量tau蛋白，长度约为352~441个氨基酸(约45~68 kDa)，主要分布在中枢神经系统；高分子量tau蛋白，约110~130 kDa，主要分布于外周神经系统。鼠类tau蛋白氨基酸序列和人类相似，仅在N端有14个氨基酸不同，成年鼠只表达4R tau，而在成年人脑内3R tau和4R tau表达量近似相等 [<xref ref-type="bibr" rid="hanspub.20732-ref3">3</xref>] 。正常人脑tau蛋白的功能主要表现在以下两个方面：1) 与管蛋白结合形成微管；2) 与已经形成的微管结合以维持其稳定性。正常生理条件下，大脑中tau蛋白存在于神经元的轴突中，可促进微管蛋白聚集成微管并增强其稳定性、维持细胞的生长发育，且在神经系统的形成和轴突的通讯传导中起至关重要的作用 [<xref ref-type="bibr" rid="hanspub.20732-ref4">4</xref>] 。</p></sec><sec id="s5"><title>3. Tau病</title><p>Tau病是微管结合蛋白的一种tau蛋白的异常疾病的总称。具体是指神经细胞内、神经胶质细胞内异常磷酸化tau蛋白蓄积的神经变性疾病。如阿尔茨海默病(AD)、皮克病、癫痫、额颞叶痴呆、皮质基底节变性、进行性核上性麻痹、朊蛋白病等。Tau病是以异常磷酸化Tau (P-tau)蛋白聚集为病理特点的年龄相关性神经变性病 [<xref ref-type="bibr" rid="hanspub.20732-ref5">5</xref>] 。Tau蛋白异常磷酸化修饰在AD及其他tau病的发病机制中起重要作用。P-tau蛋白丧失了催化微管装配和稳定微管结构的正常生物活性，不仅与正常微管相关蛋白互相竞争，影响微管形成，且促使正常微管相关蛋白与微管分离，使微管崩解，轴突变性，影响神经递质的合成、运输、释放和摄取，造成神经细胞间的物质运输障碍，从而导致神经退行性变 [<xref ref-type="bibr" rid="hanspub.20732-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.20732-ref7">7</xref>] 。</p></sec><sec id="s6"><title>4. Tau的过度磷酸化</title><p>Tau蛋白有多于45个磷酸化位点，其中大多位于脯氨酸富集区(即磷酸化位点富集区，大多为172~251位点区域)和C-末端尾区(大多位于368~441位点区域) [<xref ref-type="bibr" rid="hanspub.20732-ref8">8</xref>] 。在tau蛋白这些区域的过度磷酸化可影响它与微管的结合能力 [<xref ref-type="bibr" rid="hanspub.20732-ref9">9</xref>] 。更为严重的是，tau蛋白的过度磷酸化可促进和增强tau蛋白的聚集 [<xref ref-type="bibr" rid="hanspub.20732-ref10">10</xref>] 。许多证据表明，在阿尔茨海默病及其他tau蛋白引起的病理过程中tau蛋白的过度磷酸化可能发生在最早期 [<xref ref-type="bibr" rid="hanspub.20732-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.20732-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.20732-ref13">13</xref>] 。</p><p>正常成人大脑中tau蛋白只有2~3个氨基酸残基被磷酸化，但在AD和其他tau病变患者大脑中，tau蛋白被过度磷酸化，每克分子tau蛋白的磷酸含量最多增至9 mol/L [<xref ref-type="bibr" rid="hanspub.20732-ref14">14</xref>] 。在AD患者脑中存在三种tau蛋白：1) 细胞质中正常的磷酸化tau (C-tau)；2) 可溶性异常磷酸化的tau；3) 聚集成PHF (成对螺旋丝)的异常磷酸化的tau (PHF-tau)。目前，在PHF-tau中已鉴定出45个磷酸化位点 [<xref ref-type="bibr" rid="hanspub.20732-ref8">8</xref>] ，且AD患者脑内的tau蛋白持续保持磷酸化状态。由于Thr181、Thr231、Ser396、Ser404等位点的过度磷酸化被认为可预示轻度认知功能障碍向AD过渡，故多数学者选取这些位点进行研究，这有助于临床尽早发现AD等tau病，从而进行早期干预治疗 [<xref ref-type="bibr" rid="hanspub.20732-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.20732-ref16">16</xref>] 。</p></sec><sec id="s7"><title>5. Tau过度磷酸化的可能机制</title><p>蛋白激酶和蛋白磷酸酯酶(protein phosphatase，PP)的平衡紊乱可能是导致tau蛋白过度磷酸化的重要原因 [<xref ref-type="bibr" rid="hanspub.20732-ref17">17</xref>] 。Tau蛋白发生过度磷酸化可能是蛋白激酶活性上调或磷酸酯酶活性下调造成。</p><sec id="s7_1"><title>5.1. 蛋白激酶</title><p>已有研究证明，tau蛋白高度磷酸化和神经原纤维缠结的形成与蛋白激酶的异常活化有关 [<xref ref-type="bibr" rid="hanspub.20732-ref18">18</xref>] 。催化tau蛋白磷酸化反应的蛋白激酶有脯氨酸(Pro)指导的蛋白激酶和非脯氨酸指导的蛋白激酶两类。脯氨酸指导的蛋白激酶，如糖原合成激酶3 (GSK-3)和细胞周期依赖性蛋白激酶5，主要磷酸化Ser-Pro或Thr-Pro (丝氨酸/苏氨酸后续有脯氨酸连接) tau蛋白形式；而非脯氨酸指导的蛋白激酶，如蛋白激酶A、蛋白激酶C、钙调蛋白依赖性激酶、纤溶酶和糖皮质激素依赖性蛋白激酶，主要磷酸化丝氨酸或苏氨酸残基，且不需要脯氨酸指导。</p><p>GSK-3是一种多功能的脯氨酸指导的蛋白激酶，主要有GSK-3α和GSK-3β两种亚型。研究发现，tau蛋白磷酸化水平会随着GSK-3β的过度表达而增加 [<xref ref-type="bibr" rid="hanspub.20732-ref19">19</xref>] 。GSK-3β是催化tau蛋白配对螺旋样纤维(PHF)1 (即Ser396/404)位点磷酸化的主要激酶，而此位点的过度磷酸化可引起神经原纤维缠结的形成，表明GSK-3β是AD中tau蛋白过度磷酸化的重要激酶 [<xref ref-type="bibr" rid="hanspub.20732-ref20">20</xref>] 。有研究报道，脑缺血/再灌注引起的tau蛋白过度磷酸化可能与GSK-3β活性增高有关，但这一报道还需进一步证实 [<xref ref-type="bibr" rid="hanspub.20732-ref21">21</xref>] 。有研究指出Aβ(42)诱导神经元损伤中有GSK-3β的激活，而GSK-3β抑制剂可减弱tau蛋白的磷酸化，表明神经元中Aβ(42)可通过GSK-3β途径增加tau蛋白异常磷酸化，从而引起tau蛋白介导的神经退行性变 [<xref ref-type="bibr" rid="hanspub.20732-ref22">22</xref>] 。这可能是tau与Aβ间的内在联系，提示Aβ能诱导tau蛋白过度磷酸化。</p><p>Jicha等 [<xref ref-type="bibr" rid="hanspub.20732-ref23">23</xref>] 用只识别PKA (蛋白激酶A)催化的tau蛋白磷酸化位点的tau蛋白抗体发现Ser-214位点磷酸化在AD患者神经元无缠结早期就存在，并贯穿缠结形成的全过程，提示PKA对tau相应位点的磷酸化在AD神经元变性早期就有作用。另有研究显示，葡萄糖代谢降低可直接影响到海马神经细胞内O-GlcNAc的修饰水平下降，结果导致tau蛋白在许多位点上的磷酸化水平增加 [<xref ref-type="bibr" rid="hanspub.20732-ref24">24</xref>] 。O-GlcNAc糖基化修饰是一种单糖β-N-乙酰氨基葡萄糖通过糖苷键与丝氨酸/苏氨酸结合形成的蛋白质糖基化修饰，这种糖基化修饰与磷酸化修饰在胞浆蛋白中同时出现 [<xref ref-type="bibr" rid="hanspub.20732-ref25">25</xref>] 。当神经细胞膜上GLUT3 (葡萄糖转运子3)水平下降，由神经细胞外转入到细胞内的葡萄糖浓度降低致代谢受损，O-GlcNAc糖基化修饰水平下调，而使同一位点磷酸化修饰程度增高。</p></sec><sec id="s7_2"><title>5.2. 蛋白磷酸酯酶</title><p>已在细胞、脑片、动物水平证实：蛋白磷酸酯酶在AD等神经元退化中起了重要的作用，抑制蛋白磷酸酯酶活性，可诱导tau的过度磷酸化和聚集 [<xref ref-type="bibr" rid="hanspub.20732-ref26">26</xref>] 。研究证实，PP-2A、PP-2B和PP-1等均可使AD脑中易溶型异常磷酸化的tau和PHF-tau不同程度的去磷酸化，从而不同程度地恢复tau蛋白促微管组装的生物学活性 [<xref ref-type="bibr" rid="hanspub.20732-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.20732-ref28">28</xref>] 。在多种蛋白磷酸酯酶中，PP-2A是最重要的磷酸酯酶，其次为PP-1、PP-5和PP-2B。在AD患者脑内，一些磷酸酯酶的mRNA和蛋白表达量均有所减少，活性下降，尤其是PP-2A活性降低，促使tau的过度磷酸化水平增高。Gong等(2000)用冈田酸处理有代谢活性的脑组织活片使PP-2A抑制70%时，可观察到tau的多个位点的AD样磷酸化，其分布也类似于AD。PP-2A可能是使AD异常磷酸化的tau去磷酸化活性最强的磷酸酯酶。PP-2A活性受抑制以后，tau的去磷酸化过程减慢而使tau处于高磷酸化状态，还可能通过某些激酶的激活间接发挥作用，如Ca<sup>2+</sup>/CaM依赖性蛋白激酶Ⅱ [<xref ref-type="bibr" rid="hanspub.20732-ref29">29</xref>] 、cAMP依赖性蛋白激酶 [<xref ref-type="bibr" rid="hanspub.20732-ref30">30</xref>] 、丝裂原激活的蛋白激酶 [<xref ref-type="bibr" rid="hanspub.20732-ref31">31</xref>] 等，在体外可催化tau的某些位点发生AD样磷酸化，并使tau维持高磷酸化状态。因此，恢复或上调PP-2A之活性，阻止tau蛋白的过度磷酸化可能是防治AD等神经退行性疾病的有效途径。</p></sec></sec><sec id="s8"><title>6. Tau过度磷酸化的后果</title><p>AD等神经退行性疾病的发生机制尚不明确。近有研究发现，在突触后位点有内源性的tau蛋白存在，且这些突触后位点可调节PSD95-NMDA受体复合物的相互作用；而NMDA受体的激活可导致tau蛋白的特点位点磷酸化，进而通过Fyn调节tau蛋白与PSD95-NMDA受体复合物两者之间的相互作用，结果表明NMDA受体过度激活可能导致tau蛋白异常磷酸化，从而影响突触传递 [<xref ref-type="bibr" rid="hanspub.20732-ref32">32</xref>] 。Tau的过度磷酸化使它与微管蛋白的结合只有正常tau蛋白的10%，且束缚了tau蛋白对微管的稳定，造成神经纤维退化及功能障碍，而形成神经原纤维缠结(NFTs)。在病理状况下(如在AD中)，各种致病因素通过不同的病理途径导致tau蛋白激酶与磷酸酯酶功能失衡，进而引起tau蛋白的异常高水平磷酸化，以致其含磷酸盐受体的残基大多被磷酸化；从而使tau蛋白与微管结合的动态平衡被打破，造成游离性tau蛋白片段异常增多，最终使tau蛋白发生异常聚集、纤维化和神经原纤维缠结形成 [<xref ref-type="bibr" rid="hanspub.20732-ref33">33</xref>] 。另有研究者发现，把野生型的tau-4R基因转入到野生型小鼠时，可启动半胱氨酸天冬氨酸蛋白酶的激活、tau蛋白的裂解和神经原纤维缠结的形成；但是，含有NFTs的神经元却能长期存活，这表明是可溶性的tau蛋白而非NFTs才是导致神经退行性病变(Tau蛋白病)的重要机制 [<xref ref-type="bibr" rid="hanspub.20732-ref34">34</xref>] 。更有研究认为，可溶性的tau蛋白而非NFTs介导了病变对微管稳定性的破坏和毒性作用 [<xref ref-type="bibr" rid="hanspub.20732-ref35">35</xref>] 。尽管NFTs本身无活性，对微管组装也无作用，但它可成为一占位性斑块阻塞微管并导致神经元细胞的损伤，有可能对神经退行性Tau蛋白病的发病起一定的促进作用。</p></sec><sec id="s9"><title>7. 结语</title><p>Tau蛋白作为一种主要的微管相关蛋白，其异常修饰在神经退行性疾病中起重要的作用。对tau蛋白的相关功能及调控机制进行深入的研究可能为了解神经退行性疾病的临床和病理生理机制提供某些新的思路，为此类疾病的早期诊断和治疗提供一定的依据。以过度磷酸化的tau蛋白为核心形成的神经原纤维缠结是AD脑中的重要标志，糖基化与泛素化等与其关系密切。Tau蛋白功能异常改变可能是神经元功能障碍及死亡的必要环节，因而针对tau蛋白的代谢及功能作为靶点对积极预防和治疗AD等神经退行性疾病是非常有益的。由于Tau蛋白的异常修饰涉及多种酶，可在此基础上发展新的治疗AD药物。应用磷酸酯酶及该酶激活剂类药物，降低Tau蛋白磷酸化过程，可能对AD患者的神经元纤维退化有抑制甚至逆转的作用。也可考虑用分解糖基的特异糖苷酶，限制Tau蛋白的异常糖基化。</p></sec><sec id="s10"><title>文章引用</title><p>陈亦刚. Tau的异常磷酸化与Tau病Abnormally Phosphorylated Tau and Tauopathies[J]. 国际神经精神科学杂志, 2017, 06(02): 7-12. http://dx.doi.org/10.12677/IJPN.2017.62002</p></sec><sec id="s11"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.20732-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kosik, K.S. (1993) The Molecular and Cellular Biology of Tau. Brain Pathology, 3, 39-43.  
&lt;br&gt;https://doi.org/10.1111/j.1750-3639.1993.tb00724.x</mixed-citation></ref><ref id="hanspub.20732-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Marx, J. (2007) A New Take on Tau. Science, 316, 1416-1417. &lt;br&gt;https://doi.org/10.1126/science.316.5830.1416</mixed-citation></ref><ref id="hanspub.20732-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Andorfer, C., Kress, Y., Espinoza, M., et al. (2003) Hyperphosphorylation and Aggregation of Tau in Mice Expressing Normal Human Tau Isoforms. Journal of Neurochemistry, 86, 582-590.  
&lt;br&gt;https://doi.org/10.1046/j.1471-4159.2003.01879.x</mixed-citation></ref><ref id="hanspub.20732-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">吴琪. Alzheimer病神经元纤维缠结tau蛋白研究[J]. 中国神经精神疾病杂志, 2000, 26(1): 63-64.</mixed-citation></ref><ref id="hanspub.20732-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">马云峰, 王湘庆, 郎森阳. 微管相关蛋白tau蛋白及tau病的研究进展[J]. 解放军医学院学报, 2015, 36(6): 621- 624.</mixed-citation></ref><ref id="hanspub.20732-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Amniai, L., Barbier, P., Sillen, A., et al. (2009) Alzheimer Disease Specific Phosphoepitopes of Tau Interfere with Assembly of Tubulin but Not Binding to Microtubules. The FASEB Journal, 23, 1146-1152.  
&lt;br&gt;https://doi.org/10.1096/fj.08-121590</mixed-citation></ref><ref id="hanspub.20732-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Avila, J. (2008) Tau Kinases and Phosphatases. Journal of Cellular and Molecular Medicine, 12, 258-259.  
&lt;br&gt;https://doi.org/10.1111/j.1582-4934.2007.00214.x</mixed-citation></ref><ref id="hanspub.20732-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hanger, D.P., Anderton, B.H. and Noble, W. (2009) Tau Phosphorylation: The Therapeutic Challenge for Neurodegenerative Disease. Trends in Molecular Medicine, 15, 112-119. &lt;br&gt;https://doi.org/10.1016/j.molmed.2009.01.003</mixed-citation></ref><ref id="hanspub.20732-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Liu, F., Li, B., Tung, E.J., et al. (2007) Site-Specific Effects of Tau Phosphorylation on Its Microtubule Assembly Activity and Self-Aggregation. European Journal of Neuroscience, 26, 3429-3436.  
&lt;br&gt;https://doi.org/10.1111/j.1460-9568.2007.05955.x</mixed-citation></ref><ref id="hanspub.20732-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Rankin, C.A., Sun, Q. and Gamblin, T.C. (2005) Pseu-do-Phosphorylation of Tau at Ser202 and Thr205 Affects Tau Filament Formation. Molecular Brain Research, 138, 84-93.</mixed-citation></ref><ref id="hanspub.20732-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Mondragón-Rodríguez, S., Basurto-Islas, G., Santa-Maria, I., et al. (2008) Cleavage and Conformational Changes of Tau Protein Follow Phosphorylation during Alzheimer’s Disease. International Journal of Experimental Pathology, 89, 81-90. &lt;br&gt;https://doi.org/10.1111/j.1365-2613.2007.00568.x</mixed-citation></ref><ref id="hanspub.20732-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Mondragón-Rodríguez, S., Basurto-Islas, G., Lee, H., et al. (2010) Causes versus Effects: The Increasing Complexities of Alzheimer’s Disease Pathogenesis. Expert Review of Neurotherapeutics, 10, 683-691.  
&lt;br&gt;https://doi.org/10.1586/ern.10.27</mixed-citation></ref><ref id="hanspub.20732-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mondragón-Rodríguez, S., Mena, R., Binder, L.I., et al. (2008) Conformational Changes and Cleavage of Tau in Pick Bodies Parallel the Early Processing of Tau Found in Alzheimer Pathology. Neuropathology and Applied Neurobiology, 34, 62-75.</mixed-citation></ref><ref id="hanspub.20732-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Medeiros, R., Baglietto-Vargas, D. and Laferla, F.M. (2011) The Role of Tau in Alzheimer’s Disease and Disorders. CNS Neuroscience &amp; Therapeutics, 17, 514-524. &lt;br&gt;https://doi.org/10.1111/j.1755-5949.2010.00177.x</mixed-citation></ref><ref id="hanspub.20732-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Diniz, B.S., Pinto-Janior, J.A. and Forlenza, O.V. (2008) Do CSF Total Tau, Phosphorylated Tau and β-Amyloid 42 Help to Predict Progression of Mild Cognitive Impairment to Alzheimer’s Disease? A Systematic Review and Meta- Analysis of the Literature. The World Journal of Biological Psychiatry, 9, 172-182.  
&lt;br&gt;https://doi.org/10.1080/15622970701535502</mixed-citation></ref><ref id="hanspub.20732-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ewers, M., Buerger, K., Teipel, S.J., et al. (2007) Multicenter Assessment of CSF-Phosphorylated Tau for the Prediction of Conversion of MCI. Neurology, 69, 2205-2212. &lt;br&gt;https://doi.org/10.1212/01.wnl.0000286944.22262.ff</mixed-citation></ref><ref id="hanspub.20732-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Gong, C.X., Liu, F., Grundke-Iqbal, I., et al. (2006) Dysregulation of Protein Phosphorylation/Dephosphorylation in Alzheimer’s Disease: A Therapeutic Target. BioMed Research International, No. 3, Article ID: 31825.</mixed-citation></ref><ref id="hanspub.20732-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Hemandez, P., Lee, G., Sjoberg, M., et al. (2009) Tau Phosphorylation by cdk5 and Fyn in Response to Amyloid Peptide Aβ25-35: Involvement of Lipid Rafts. Journal of Alzheimer’s Disease, 16, 149-156.  
&lt;br&gt;https://doi.org/10.3233/JAD-2009-0933</mixed-citation></ref><ref id="hanspub.20732-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Cuehillo-Ibanez, I., Seereeram, A., Byers, H.L., et al. (2008) Phosphorylation of Tau Regulates Its Axonal Transport by Controlling Its Binding to Kinesin. The FASEB Journal, 22, 3186-3195. &lt;br&gt;https://doi.org/10.1096/fj.08-109181</mixed-citation></ref><ref id="hanspub.20732-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Lee, S., Hall, G.F., Shea, T.B., et al. (2011) Potentiation of Tau Aggregation by cdk5 and GSK3β. Journal of Alzheimer’s Disease, 26, 355-364.</mixed-citation></ref><ref id="hanspub.20732-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H., Zhao, H., Ye, Y., et al. (2010) Focal Cerebral Ischemia Induces Alzheimer’s Disease-Like Pathological Change in Rats. Journal of Huazhong University of Science and Technology (Medical Sciences), 30, 29-36.  
&lt;br&gt;https://doi.org/10.1007/s11596-010-0106-4</mixed-citation></ref><ref id="hanspub.20732-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Park, H., Kam, T.I., Kim, Y., et al. (2012) Neuropathogenic Role of Adenylate Kinase-1 in Aβ-Mediated Tau Phosphorylation via AMPK and GSK3β. Human Molecular Genetics, 21, 2725-2737. &lt;br&gt;https://doi.org/10.1093/hmg/dds100</mixed-citation></ref><ref id="hanspub.20732-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Jicha, G.A., Weaver, C., Lane, E., et al. (1999) cAMP-Dependent Protein Kinase Phosphorylations on Tau in Alzheimer’s Disease. The Journal of Neuroscience, 19, 7486-7494.</mixed-citation></ref><ref id="hanspub.20732-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Liu, F., Iqbal, K., Grundke-Iqbal, I., et al. (2004) O-GlcNAcylation Regulates Phosphorylation of Tau: A Mechanism Involved in Alzheimer’s Disease. Proceedings of the National Academy of Sciences of the United States of America, 101, 10804-10809. &lt;br&gt;https://doi.org/10.1073/pnas.0400348101</mixed-citation></ref><ref id="hanspub.20732-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Lefebvre, T., Ferreira, S., Dupont-Wallois, L., et al. (2003) Evidence of a Balance between Phosphorylation and O-GlcNAc Glycosylation of Tau Proteins—A Role in Nuclear Localization. Biochimica et Biophysica Acta, 1619, 167-176.</mixed-citation></ref><ref id="hanspub.20732-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Tian, Q. and Wang, J.Z. (2002) Role of Protein Phosphatases on Alzheimer Disease. Neurosignals, 11, 262-269.  
&lt;br&gt;https://doi.org/10.1159/000067425</mixed-citation></ref><ref id="hanspub.20732-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, C.E., Tian, Q., Wei, W., et al. (2008) Homoeysteine Induces Tau Phosphorylation by Inactivating Protein Phosphatase 2A in Rat Hippocampus. Neurobiology of Aging, 29, 1654-1665.  
&lt;br&gt;https://doi.org/10.1016/j.neurobiolaging.2007.04.015</mixed-citation></ref><ref id="hanspub.20732-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Liu, R. and Wang, J.Z. (2009) Protein Phosphatase 2A in Alzheimer’s Disease. Pathophysiology, 16, 273-277.  
&lt;br&gt;https://doi.org/10.1016/j.pathophys.2009.02.008</mixed-citation></ref><ref id="hanspub.20732-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Bennecib, M., Gong, C.X., Grundke-Iqbal, I., et al. (2001) Inhibition of PP-2A Up-Regulates CaMII in Rat Forebrain and Induces Hyperphosphorylation of Tau at Ser262/356. FEBS Letters, 490, 15-22.  
&lt;br&gt;https://doi.org/10.1016/S0014-5793(01)02127-5</mixed-citation></ref><ref id="hanspub.20732-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Li, L., Sengupta, A., Haque, N., et al. (2004) Memantine Inhibits and Reverses the Alzheimer Type Abnormal Hyperphosphorylation of Tau and Associated Neurodegeneration. FEBS Letters, 566, 261-269.  
&lt;br&gt;https://doi.org/10.1016/j.febslet.2004.04.047</mixed-citation></ref><ref id="hanspub.20732-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Iqbal, K. and Grundke-Iqbal, I. (2005) Pharmacological Approaches of Neurofibrillary Degeneration. Current Alzheimer Research, 2, 335-341. &lt;br&gt;https://doi.org/10.2174/1567205054367810</mixed-citation></ref><ref id="hanspub.20732-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Mondragón-Rodríguez, S., Trillaud-Doppia, E., Dudilot, A., et al. (2012) Interaction of Endogenous Tau Protein with Synaptic Proteins Is Regulated by N-Methyl-D-Aspartate Receptor-Dependent Tau Phosphorylation. Journal of Biological Chemistry, 287, 32040-32053. &lt;br&gt;https://doi.org/10.1074/jbc.M112.401240</mixed-citation></ref><ref id="hanspub.20732-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Xu, S.H., Brunden, K.R., Trojanowski, J.Q., et al. (2010) Characterization of Tau Fibrillization in Vitro. Alzheimer’s &amp; Dementia, 6, 110-117. &lt;br&gt;https://doi.org/10.1016/j.jalz.2009.06.002</mixed-citation></ref><ref id="hanspub.20732-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Martina, L., Latypovaa, X. and Terroa, F. (2011) Post-Translational Modifications of Tau Protein: Implication for Alzheimer’s Disease. Neurochemistry International, 58, 458-471.</mixed-citation></ref><ref id="hanspub.20732-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Spires-Jones, T.L., Kopeikina, K.J., Koffie, R.M., et al. (2011) Are Tangles as Toxic as They Look? Journal of Molecular Neuroscience, 45, 438-444. &lt;br&gt;https://doi.org/10.1007/s12031-011-9566-7</mixed-citation></ref></ref-list></back></article>